In light of the crucial role of the BCR-ABL tyrosine kinase in chronic myelogenous leukemia, TKIs have become the first-line therapy for most patients with chronic myelogenous leukemia [4], [32],[33]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.